Women who received HPV Vaccine May Need Another Shot

Women who received HPV Vaccine May Need Another Shot


Women who receive the human papillomavirus (HPV) vaccine may be more likely to be infected with certain high-risk strains of the virus than women who do not get the vaccine, according to a new study.

The findings suggest that, although the vaccine is effective in protecting against four strains of HPV, women who received it may still benefit from getting another, recently approved HPV vaccine that protects against nine strains of the virus, the researchers said.

“Vaccinated women who got the quadrivalent [four-strain] vaccine may get the nine-valent [strain] vaccine as further protection for them,” said Fangjian Guo, a postdoctoral fellow at the University of Texas Medical Branch and one of the researchers on the new study. Guo noted that this is not an official recommendation, and that more research is needed to confirm the findings. Currently, the Centers for Disease Control and Prevention recommends that girls and young women ages 9 to 26 get any HPV vaccine to protect against cervical cancer, as some strains of HPV have been linked to cervical cancer.

The new study was presented this week here at the meeting of the American Association for Cancer Research. It has not yet been published in a peer-reviewed journal.

For the new study, Guo and his colleagues analyzed information from nearly 600 women ages 20 to 26, including 80 women who had received the original Gardasil HPV vaccine, which protects against four HPV types — 6, 11, 16 and 18. There are many types of HPV, and some can lead to cervical cancer if the body does not clear the infection after many years. HPV types 16 and 18 cause the majority of cervical cancers.

Women in the study who received the Gardasil vaccine were, indeed, less likely to be infected with the four strains of the virus included the vaccine: About 11 percent of vaccinated women were infected with HPV 6, 11, 16 or 18, compared with nearly 20 percent of unvaccinated women.

However, the women who received the vaccine were more likely to be infected with other high-risk HPV strains not included in the vaccine. About 61 percent of the women who received the vaccine were infected with another type of high-risk HPV, compared with 40 percent of women who did not receive the vaccine. (HPV strains are considered “high risk” if they can cause cellular changes that can eventually lead to cancer.)

After the researchers took into account factors that could affect a person’s risk of HPV infection (including his or her number of sexual partners), the women who received the original HPV vaccine still had about a 40 percent greater risk of being infected with a high-risk HPV strain not included in the vaccine. [10 Do’s and Don’ts to Reduce Your Risk of Cancer]

It’s unclear why the vaccinated women were more likely to be infected with other high-risk strains, the researchers said.

The new findings suggest that women previously vaccinated against HPV may benefit from a new HPV vaccine, called Gardasil 9, which protects against the original four strains plus five more strains (31, 33, 45, 52 and 58) of HPV that cause about 20 percent of cervical cancers, the researchers said. Gardasil 9 wasapproved in December 2014 for women ages 9 to 26.

And if a woman is already infected with HPV, the HPV vaccine cannot eliminate this infection, Guo noted. Younger women and girls who have not acquired an HPV infection would benefit most from the new vaccine, Guo said.

Because the new study looked at women at one point in time, the researchers could not determine women’s risk of going on to develop cervical cancer. However previous studies have found that the HPV vaccine lowers the rate of precancerous lesions in women who are vaccinated.

Studies that follow women over time would be needed in order to determine women’s risk of developing cervical cancer if they were vaccinated but were to still become infected with a high-risk strain of HPV, Guo said.

The new study “highlights the need to continue to pursue additional strategies to control HPV infection,” said Dr. Kunle Odunsi, deputy director and chairman of the department of gynecologic oncology at Roswell Park Cancer Institute in Buffalo, New York, who was not involved in the study.

“We need to remember that there are more than 80 HPV types, and some of them can still be associated with risk of cervical malignant disease,” Odunsi said.

Future vaccines could include even more strains of the virus, Odunsi said.

Based on the new findings, Odunsi said that, in his opinion, women who received the quadrivalent vaccine should probably get the nine-valent vaccine.

Dr. Shashikant Lele, clinical chief of gynecologic oncology, also of Roswell Park, said he would like to see the new findings replicated, because it’s not clear why women who were vaccinated with the quadrivalent vaccine would be more prone to other HPV infections than women who had not received the vaccine. “That doesn’t make sense to me,” Lele said.

In addition, it’s not clear whether women who received the quadrivalent vaccine would benefit from the nine-valent vaccine, so studies need to be conducted to test this hypothesis, Lele said.


Copyright 2015 LiveScience, a Purch company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

1 Comment

  1. redpill Reply

    There are over 100 strains of HPV, only about 15 of which can “contribute” to cervical.There are many other co-factors just like with other forms of cancer. One brand of gardasil has 4 strains, one has 9 strains of VLP. The 9 stains version surpasses the FDA recommended allowance of aluminum that can be given to a person.

    -The incubation period for HPV averages 20 years with the median age of sufferers being 48. Which means no one can confirm if the vaccine works for at least 15 years. Some reports state 20. Merck/CDC stated in December2012 during the Katie Couric show via their Rep that the vaccines
    duration is 2-4 years. There is to date no scientific data to confirm that because cervical cancer takes 15-20 years to develop in the average woman. See the contradiction here. So if a child begins the jabs at 9-does she get one every 2 years or 4 for the next 15 years? That means she would have accumulated in her body 225 mcg of aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) per dose 675 mcg for the first 3 shot round. Multiple that by
    16 doses at 675 per 3 shot round if the young lady is re-vaccinated every two years as recommended by the CDC. That would mean she has accumulated 3600 mcg of aluminum. Every 4 years because the CDC has posted contradictory information that would be 2015 mcg aluminum.
    Look at this short video on the affects Aluminum has on the body:
    The Effect of Aluminum in Vaccines on Humans: https://www.youtube(dot)com/watch?v=yCzdliixnmI

    -The finding of HPV viral DNA integrated in most cellular genomes of cervical carcinomas supports epidemiologic data linking this agent to cervical cancer however, direct causation has not been demonstrated.
    Cervical Cancer Prevention, Health Professional Version, National Cancer Institute (NCI)

    -While there are well-established cancer registries in the United States, it will take decades before the impact of vaccine on cervical cancer is observed. More proximal measures of vaccine impact include outcomes such as prevalence of HPV vaccine types, incidence of cervical pre-cancers and genital warts.
    Post-licensure monitoring of HPV vaccine in the United States, Centers for Disease Control and Prevention,Vaccine.2010 Jul 5;28 (30):4731-7. Epub 2010 Feb 25,

Leave a Reply

Your email address will not be published. Required fields are marked *